ARTICLE | Company News
Novavax, PATH infectious news
July 23, 2012 7:00 AM UTC
Not-for-profit PATH awarded Novavax about $2 million to support a dose-ranging Phase II trial of Novavax's RSV-F vaccine to vaccinate women of childbearing age against respiratory syncytial virus (RSV...